Aequus Pharmaceuticals Overview

  • Founded
  • 2013
Founded
  • Status
  • Public
  • Employees
  • 14
Employees
  • Stock Symbol
  • AQS
Stock Symbol
  • Investments
  • 3
  • Share Price
  • $0.08
  • (As of Friday Closing)

Aequus Pharmaceuticals General Information

Description

Aequus Pharmaceuticals Inc is a Canada based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. Aequus is developing a pipeline of products in neurology and psychiatry. The company's launched and pipeline products are Tacrolimus IR, Vistitan, AQS1304, AQS1303, and others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Delivery
Stock Exchange
TSX
Primary Office
  • 200 Granville Street
  • Suite 2820
  • Vancouver, British Columbia V6C 1S4
  • Canada
+1 (604) 000-0000

Aequus Pharmaceuticals Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aequus Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.08 $0.08 $0.08 - $0.23 $11M 133M 81.2K

Aequus Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 11,259 10,598 8,443 8,393
Revenue 2,139 1,932 1,230 1,088
EBITDA (926) (238) (1,799) (2,022)
Net Income (1,302) (779) (2,340) (2,163)
Total Assets 3,613 2,458 1,280 1,466
Total Debt 1,687 1,822 1,697 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aequus Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aequus Pharmaceuticals‘s full profile, request access.

Request a free trial

Aequus Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Aequus Pharmaceuticals Inc is a Canada based specialty pharmaceutical company. The firm's operating segments are the Com
Pharmaceuticals
Vancouver, Canada
14 As of 2020
000.00
000000000 000.00

0000000

labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris ni
000000000000000
Dublin, Ireland
00000 As of 0000
000 0000-00-00
000000&0

000000 0

cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cul
0000 00000000
Parsippany, NJ
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aequus Pharmaceuticals Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Perrigo Company Corporation Dublin, Ireland 00000 000000&0
000000 00000000000 Formerly VC-backed Parsippany, NJ 000 00000 00000000 00000
0000 0000000000000 Corporate Backed or Acquired Haifa Bay, Israel 0000 0000 00000000000
You’re viewing 3 of 3 competitors. Get the full list »

Aequus Pharmaceuticals Patents

Aequus Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20180250281-A1 Transdermal delivery of doxylamine succinate and pyridoxine hydrochloride Abandoned 17-Aug-2015 00000000000
US-20170049759-A1 Transdermal and/or topical delivery systems composed of doxylamine succinate and pyridoxine hydrochloride in combination, or alone Granted 17-Aug-2015 00000000000
US-10500196-B2 Transdermal and/or topical delivery systems composed of doxylamine succinate and pyridoxine hydrochloride in combination, or alone Active 17-Aug-2015 00000000000
CA-2995431-A1 Transdermal delivery of doxylamine succinate and pyridoxine hydrochloride Pending 17-Aug-2015 00000000000
EP-3337480-A1 Transdermal delivery of doxylamine succinate and pyridoxine hydrochloride Pending 17-Aug-2015 A61K31/4415
To view Aequus Pharmaceuticals’s complete patent history, request access »

Aequus Pharmaceuticals Executive Team (9)

Name Title Board Seat Contact Info
Grant Larsen Executive
Ian Ball Executive
Douglas Janzen Chief Executive Officer & Chairman
Ann Fehr Chief Financial Officer, Finance & Company Secretary
Anne Stevens Director & Board Member
You’re viewing 5 of 9 executive team members. Get the full list »

Aequus Pharmaceuticals Board Members (6)

Name Representing Role Since
Anne Stevens Self Director & Board Member 000 0000
Christopher Clark Self Board Member 000 0000
Douglas Janzen Self Chief Executive Officer & Chairman 000 0000
Jason Flowerday Self Board Member 000 0000
Marc Lustig Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Aequus Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aequus Pharmaceuticals Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 22-Sep-2020 00000 0000 Distributors/Wholesale
00000000-0000 11-Jan-2018 00000 0000 Biotechnology 0000000 0
TeOra Health 28-Jul-2015 Merger/Acquisition 00.000 Other Commercial Services 0000000 0
To view Aequus Pharmaceuticals’s complete investments and acquisitions history, request access »